Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Prevalence of Second Cancers in Patients with Polycythemia Vera (PV): A Retrospective Analysis of US Real-World Claims Data

Naveen Pemmaraju, Alina Markova, Lucia Masarova, Nancy Reaven, Susan Funk, Pedro Oyuela, Frank Valone, Phil Dinh, Lucy Bellamy, Nikita Modi, Arturo Molina, Suneel Gupta

Blood (2023) 142 (Supplement 1): 3190.

https://doi.org/10.1182/blood-2023-180045

Published: 2023

Journal Articles

Durability of Hematocrit Control in Polycythemia Vera with the First-in-Class Hepcidin Mimetic Rusfertide: Two-Year Follow up Results from the Revive Study

Ellen K. Ritchie, Kristen Marie Pettit, Andrew T. Kuykendall, Marina Kremyanskaya, Naveen Pemmaraju, Sarita Khanna, Arturo Molina, Suneel Gupta

Blood (2023) 142 (Supplement 1): 745.

https://doi.org/10.1182/blood-2023-178253

Published: 2023

Journal Articles

Real-World Analysis of Thromboembolic Event Rates in Patients in the United States with Polycythemia Vera

Andrew T. Kuykendall, Abdulraheem Yacoub, Nancy Reaven, Susan Funk, Pedro Oyuela, Frank Valone, Phil Dinh, Lucy Bellamy, Nikita Modi, Arturo Molina, Suneel Gupta

Blood (2023) 142 (Supplement 1): 137.

https://doi.org/10.1182/blood-2023-180309

Published: 2023

Journal Articles

Rusfertide Improves Markers of Iron Deficiency in Patients with Polycythemia Vera

Yelena Ginzburg, Lee Ping Chew, Nikita Modi, Suneel Gupta, Arturo Molina, Nishit B. Modi

Blood (2023) 142 (Supplement 1): 3208.

https://doi.org/10.1182/blood-2023-178334

Published: 2023

Journal Articles

Pediatric Acute Myeloid Leukemia with Co-Occurring BCR::ABL and CBFA2T3::GLIS2 Dual Fusion with Deep Response to FOLR1-Targeting Antibody Drug Conjugate Stro-002 and Tyrosine Kinase Inhibitor

Kasey Andrews, Soheil Meshinchi, Preethi Marri, Abdul H. Siddiqui, Jacek Polski, Arturo Molina, Joseph Chewning, Lisa Eidenschink Brodersen, Chad A. Hudson, Hamayun Imran

Blood (2022) 140 (Supplement 1): 11757–11758.

https://doi.org/10.1182/blood-2022-164629

Published: 2022

Journal Articles

Anti-Leukemic Activity of STRO-002 a Novel Folate Receptor-α (FR-α)-Targeting ADC in Relapsed/Refractory CBF2AT3-GLIS2 AML

Blood (2022) 140 (Supplement 1): 159–161.

https://doi.org/10.1182/blood-2022-162842

Published: 2022

Journal Articles

Therapeutic Targeting of CD74 with STRO-001 Antibody-Drug Conjugate in AML and ALL

Quy Le, Amanda R. Leonti, Thao T. Tang, Sommer Castro, Cynthia Nourigat-Mckay, LaKeisha Perkins, Rhonda E. Ries, Jenny L. Smith, Tiffany A. Hylkema, Laura Pardo, Cristina Abrahams, Kristin Bedard, Arturo Molina, Lisa Eidenschink Brodersen, Michael R. Loken, Soheil Meshinchi

Blood (2021) 138 (Supplement 1): 509.

https://doi.org/10.1182/blood-2021-151160

Published: 2021

Journal Articles

Targeting FOLR1 in High-Risk CBF2AT3-GLIS2 AML with Stro-002 FOLR1-Directed Antibody-Drug Conjugate

Quy Le, Jenny L. Smith, Thao T. Tang, Sommer Castro, Cynthia Nourigat-Mckay, LaKeisha Perkins, Benjamin J. Huang, Rhonda E. Ries, Amanda R. Leonti, Tiffany A. Hylkema, Laura Pardo, Cristina Abrahams, Kristin Bedard, Arturo Molina, Lisa Eidenschink Brodersen, Michael R. Loken, Soheil Meshinchi

Blood (2021) 138 (Supplement 1): 209.

https://doi.org/10.1182/blood-2021-153076

Published: 2021

Journal Articles

Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma

Nirav N. Shah, MD, Ahmad H. Mattour, MD, Leslie L. Popplewell, MD FACP, Charalambos Andreadis, MD, Jason M. Melear, MD, Alexander I. Spira, PhD MD FACP, Jonah Shulman, MD, Sudhir Manda, MD, John M. Burke, MD, Saurabh Chhabra, MD, Jeff P Sharman, MD, Amrita Krishnan, MD, Nina Shah, MD, Clifford DiLea, RPh, Pharm.D., Jason Kuriakose, MBA, Craig Jerome Berman, MD, Shannon L. Matheny, PhD, John P. Leonard, MD, Arturo Molina, MDMS

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-139829

Published: 2020

Journal Articles

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

Nirav N. Shah, MD, Amrita Y. Krishnan, MD, Nina D. Shah, MD, John M Burke, MD, Jason M. Melear, MD, Alexander I. Spira, PhD MD FACP, Leslie L. Popplewell, MD FRCPA, Charalambos B. Andreadis, MD, Saurabh Chhabra, MD, Jeff P. Sharman, MD, Jonathan L. Kaufman, MD, Jonathon B. Cohen, MDMS, Ruben Niesvizky, MD, Thomas G. Martin, III, MD, Clifford DiLea, RPh, Pharm.D., Jason Kuriakose, Shannon L. Matheny, PhD, John P. Leonard, MD, Arturo Molina, MDMS, FACP

Blood (2019) 134 (Supplement_1): 5329.

https://doi.org/10.1182/blood-2019-122754

Published: 2019

Journal Articles

CD74 Is Expressed in Relapsed and Refractory Multiple Myeloma and Can be Targeted with a Novel Anti-CD74 Antibody Drug Conjugate, SΤRO-001

Millicent Embry, Xiaofan Li, PhD, Abigail Yu, PhD, Cristina Abrahams, PhD, Nancy Y. Greenland, MD PhD, Kwun Wah Wen, MD PhD, Chris Jones, Venita DeAlmeida, PhD, Stellanie Krimm, Sarah Krueger, PhD, Shannon Matheny, PhD, Toni Kline, PhD, Alice Yam, PhD, Ryan Stafford, PhD, Arun P. Wiita, MD PhD, Trevor Hallam, PhD, Mark Lupher, PhD, Arturo Molina, MDMS, FACP

Blood (2017) 130 (Supplement 1): 4420.

https://doi.org/10.1182/blood.V130.Suppl_1.4420.4420

Published: 2017

Journal Articles

High Frequency of CD74 Expression in B-Cell Non-Hodgkin's Lymphoma (NHL) and Targeting with SΤRO-001, a Novel Anti-CD74 Antibody Drug Conjugate (ADC) with Potent I n Vitro Cytotoxicty and In Vivo Anti-Tumor Activity

Abigail Yu, PhD, Cristina Abrahams, PhD, Millicent Embry, Xiaofan Li, PhD, Shuchun Zhao, PhD, Robert Henningsen, Venita DeAlmeida, PhD, Shannon Matheny, PhD, Toni Kline, PhD, Alice Yam, PhD, Ryan Stafford, PhD, Yasodha Natkunam, MD PhD, Trevor Hallam, PhD, Mark Lupher, PhD, Arturo Molina, MDMS, FACP

Blood (2017) 130 (Supplement 1): 573.

https://doi.org/10.1182/blood.V130.Suppl_1.573.573

Published: 2017

Journal Articles

Targeting CD74 with Novel Antibody Drug Conjugates (ADCs) for the Treatment of B-Cell Non-Hodgkin's Lymphoma (NHL)

Blood (2016) 128 (22): 464.

https://doi.org/10.1182/blood.V128.22.464.464

Published: 2016

Journal Articles

Discovery and Preclinical Development of Novel CD74-Targeting Antibody-Drug Conjugates (ADCs) with Significant Activity in Multiple Myeloma (MM) Cell Lines and Xenograft Models

Blood (2016) 128 (22): 4465.

https://doi.org/10.1182/blood.V128.22.4465.4465

Published: 2016

Journal Articles

Inhibition of B-NHL Tumor Xenografts Following Treatment with Galiximab (Anti-CD80 mAb) and Potentiation When Combined with Chemotherapy

Mario I Vega, PhD, Hari Hariharan, PhD, Peter Chu, PhD, Tracey Murphy, PhD, Dana Clanton, PhD, Lisa Berquist, PhD, Arturo Molina, PhD, Steffan Ho, PhD, Benjamin Bonavida, Ph.D

Blood (2012) 120 (21): 4873.

https://doi.org/10.1182/blood.V120.21.4873.4873

Published: 2012

Journal Articles

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

John C. Byrd, Thomas J. Kipps, Ian W. Flinn, Januaro Castro, Thomas S. Lin, William Wierda, Nyla Heerema, James Woodworth, Steve Hughes, Shabnam Tangri, Sarah Harris, Dee Wynne, Arturo Molina, Bryan Leigh, Susan O'Brien

Blood (2010) 115 (3): 489–495.

https://doi.org/10.1182/blood-2009-08-237727

Published: 2010

Journal Articles

Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23 + lymphoma cell lines

Nuzhat I. Pathan, Peter Chu, Kandasamy Hariharan, Carolyn Cheney, Arturo Molina, John Byrd

Blood (2008) 111 (3): 1594–1602.

https://doi.org/10.1182/blood-2007-03-082024

Published: 2008

Journal Articles

Updated Results of High-Dose Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan with High-Dose Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Autologous Hematopoietic Cell Transplant (AHSCT) for Poor-Risk or Refractory B-Cell Non-Hodgkin’s Lymphoma.

Auayporn Nademanee, MD, Andrew Raubitschek, MD, Arturo Molina, MD, Joycelynne Palmer, Ph.D, Ni-Chun Tsai, MS, Amrita Krishnan, MD, Neil Kogut, MD, Stephen Forman, MD

Blood (2007) 110 (11): 1891.

https://doi.org/10.1182/blood.V110.11.1891.1891

Published: 2007

Journal Articles

A Comparison of Beam and Yttrium 90 Ibritumomab Tiuxetan (Zevalin®) in Addition to Beam (Z-BEAM) in Older Patients Undergoing Autologous Stem Cell Transplant (ASCT) for B-Cell Lymphomas: Impact of Radioimmunotherapy on Transplant Outcomes.

Amrita Y. Krishnan, MD, Auayporn Nademanee, MD, Andrew Raubitschek, MD, Henry C. Fung, MD, Arturo Molina, MD, David Yamauchi, MD, Peter M. Falk, MD, Ricardo Spielberger, MD, Joycelynne Palmer, PhD, Ni Chun Tsai, MS, MPH, Jeffrey Schriber, MD, Stephen J. Forman, MD

Blood (2006) 108 (11): 3043.

https://doi.org/10.1182/blood.V108.11.3043.3043

Published: 2006

Journal Articles

Comparison of Results from a Phase 1/2 Study of Lumiliximab (Anti-CD23) in Combination with FCR for Patients with Relapsed CLL with Published FCR Results.

John C. Byrd, MD, Januario Castro, MD, Susan O’Brien, MD, Ian W. Flinn, MD, Andres Forero-Torres, MD, Thomas J. Kipps, MD, PhD, Nyla A. Heerema, PhD, Thomas Lin, MD, Thian Kheoh, PhD, Dee Wynnem, RN, Arturo Molina, MD, MS

Blood (2006) 108 (11): 32.

https://doi.org/10.1182/blood.V108.11.32.32

Published: 2006

NARROW

Prevalence of Second Cancers in Patients with Polycythemia Vera (PV): A Retrospective Analysis of US Real-World Claims Data

Durability of Hematocrit Control in Polycythemia Vera with the First-in-Class Hepcidin Mimetic Rusfertide: Two-Year Follow up Results from the Revive Study

Real-World Analysis of Thromboembolic Event Rates in Patients in the United States with Polycythemia Vera

Rusfertide Improves Markers of Iron Deficiency in Patients with Polycythemia Vera

Pediatric Acute Myeloid Leukemia with Co-Occurring BCR::ABL and CBFA2T3::GLIS2 Dual Fusion with Deep Response to FOLR1-Targeting Antibody Drug Conjugate Stro-002 and Tyrosine Kinase Inhibitor

Anti-Leukemic Activity of STRO-002 a Novel Folate Receptor-α (FR-α)-Targeting ADC in Relapsed/Refractory CBF2AT3-GLIS2 AML

Therapeutic Targeting of CD74 with STRO-001 Antibody-Drug Conjugate in AML and ALL

Targeting FOLR1 in High-Risk CBF2AT3-GLIS2 AML with Stro-002 FOLR1-Directed Antibody-Drug Conjugate

Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

CD74 Is Expressed in Relapsed and Refractory Multiple Myeloma and Can be Targeted with a Novel Anti-CD74 Antibody Drug Conjugate, SΤRO-001

High Frequency of CD74 Expression in B-Cell Non-Hodgkin's Lymphoma (NHL) and Targeting with SΤRO-001, a Novel Anti-CD74 Antibody Drug Conjugate (ADC) with Potent I n Vitro Cytotoxicty and In Vivo Anti-Tumor Activity

Targeting CD74 with Novel Antibody Drug Conjugates (ADCs) for the Treatment of B-Cell Non-Hodgkin's Lymphoma (NHL)

Discovery and Preclinical Development of Novel CD74-Targeting Antibody-Drug Conjugates (ADCs) with Significant Activity in Multiple Myeloma (MM) Cell Lines and Xenograft Models

Inhibition of B-NHL Tumor Xenografts Following Treatment with Galiximab (Anti-CD80 mAb) and Potentiation When Combined with Chemotherapy

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23 + lymphoma cell lines

Updated Results of High-Dose Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan with High-Dose Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Autologous Hematopoietic Cell Transplant (AHSCT) for Poor-Risk or Refractory B-Cell Non-Hodgkin’s Lymphoma.

A Comparison of Beam and Yttrium 90 Ibritumomab Tiuxetan (Zevalin®) in Addition to Beam (Z-BEAM) in Older Patients Undergoing Autologous Stem Cell Transplant (ASCT) for B-Cell Lymphomas: Impact of Radioimmunotherapy on Transplant Outcomes.

Comparison of Results from a Phase 1/2 Study of Lumiliximab (Anti-CD23) in Combination with FCR for Patients with Relapsed CLL with Published FCR Results.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only